/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

KYMERA THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

KYMERA THERAPEUTICS INC share price today is $77.99, up -2.09%. The stock opened at $79.02 against the previous close of $79.57, with an intraday high of $80.91 and low of $77.23.

KYMERA THERAPEUTICS INC Share Price Chart

style
pb-0

KYMERA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

KYMERA THERAPEUTICS INC Share Price Performance

$77.99 -0.0209(-2.09%) KYMR at 23 Mar 2026 01:54 PM Biotechnology
Lowest Today 77.23
Highest Today 80.91
Today’s Open 79.02
Prev. Close 79.57
52 Week High 103.00
52 Week Low 19.45
Day’s Range: Low 77.23 High 80.91
52-Week Range: Low 19.45 High 103.00
1 day return -
1 Week return -1.98
1 month return -11.86
3 month return -7.58
6 month return +52.87
1 year return +131.09
3 year return +174.76
5 year return +66.93
10 year return -

KYMERA THERAPEUTICS INC Institutional Holdings

FMR Inc 10.94

Baker Bros Advisors LP 10.60

venBio Select Advisor LLC 9.16

Vanguard Group Inc 7.68

Bvf Inc 6.74

T. Rowe Price Associates, Inc. 6.24

Atlas Venture Life Science Advisors, LLC 5.71

Wellington Management Company LLP 5.41

BlackRock Inc 5.35

Siren, L.L.C. 4.03

Fidelity Growth Compy Commingled Pl S 3.49

Vanguard Health Care Inv 2.66

Vanguard Total Stock Mkt Idx Inv 2.60

Fidelity Growth Company Fund 2.50

State Street Corp 2.47

US Small-Cap Growth II Equity Comp 2.41

T. Rowe Price New Horizons 2.40

Capital Research Global Investors 1.91

Vanguard Small Cap Index 1.86

Geode Capital Management, LLC 1.74

American Funds SMALLCAP World A 1.70

iShares Russell 2000 ETF 1.68

T. Rowe Price Health Sciences 1.35

Driehaus Capital Management LLC 1.31

State Street® SPDR® S&P® Biotech ETF 1.20

UBS Asset Mgmt Americas Inc 1.06

T. Rowe Price New Horizons Tr-A 1.04

Vanguard Small Cap Growth Index Inv 1.04

Merck & Co Inc 0.95

Holocene Advisors, LP 0.93

COMMODORE CAPITAL LP 0.92

The Goldman Sachs Group Inc 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.80

UBS Group AG 0.79

Vanguard Explorer Inv 0.79

Eventide Healthcare & Life Sciences I 0.77

Fidelity Growth Company K6 0.71

T. Rowe Price Integrated US SmCapGrEq 0.69

T. Rowe Price Integrated US Sm Gr Eq 0.69

Fidelity Small Cap Index 0.68

KYMERA THERAPEUTICS INC Market Status

Strong Buy: 14

Buy: 3

Hold: 3

Sell: 0

Strong Sell: 0

KYMERA THERAPEUTICS INC Fundamentals

Market Cap 6360.76 M

PB Ratio 4.1119

PE Ratio 0.0

Enterprise Value 5730.26 M

Total Assets 1742.81 M

Volume 1197728

KYMERA THERAPEUTICS INC Company Financials

Annual Revenue FY23:46846000 46.8M, FY22:46826000 46.8M, FY21:72832000 72.8M, FY20:34034000 34.0M, FY19:2934000 2.9M

Annual Profit FY23:null 0.0M, FY22:46826000 46.8M, FY21:72832000 72.8M, FY20:34034000 34.0M, FY19:2934000 2.9M

Annual Net worth FY23:-167459000 -167.5M, FY22:-151831000 -151.8M, FY21:-97995000 -98.0M, FY20:-43945000 -43.9M, FY19:-41292000 -41.3M

Quarterly Revenue Q3/2025:2764000 2.8M, Q2/2025:11476000 11.5M, Q1/2025:22100000 22.1M, Q3/2024:3741000 3.7M, Q2/2024:25650000 25.7M

Quarterly Profit Q3/2025:-71330000 -71.3M, Q2/2025:9392000 9.4M, Q1/2025:22100000 22.1M, Q3/2024:1741000 1.7M, Q2/2024:23750000 23.8M

Quarterly Net worth Q3/2025:-82175000 -82.2M, Q2/2025:-76614000 -76.6M, Q1/2025:-65581000 -65.6M, Q3/2024:-62487000 -62.5M, Q2/2024:-42062000 -42.1M

About KYMERA THERAPEUTICS INC & investment objective

Company Information Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 238

Industry Biotechnology

CEO Dr. Nello Mainolfi M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

KYMERA THERAPEUTICS INC FAQs

What is the share price of KYMERA THERAPEUTICS INC today?

The current share price of KYMERA THERAPEUTICS INC is $77.99.

Can I buy KYMERA THERAPEUTICS INC shares in India?

Yes, Indian investors can buy KYMERA THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy KYMERA THERAPEUTICS INC shares in India?

You can easily invest in KYMERA THERAPEUTICS INC shares from India by:

Can I buy fractional shares of KYMERA THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of KYMERA THERAPEUTICS INC?

KYMERA THERAPEUTICS INC has a market cap of $6360.76 M.

In which sector does KYMERA THERAPEUTICS INC belong?

KYMERA THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in KYMERA THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of KYMERA THERAPEUTICS INC?

The PE ratio of KYMERA THERAPEUTICS INC is N/A and the PB ratio is 4.11.